EXPLORATION OF HYDROXYL SUBSTITUTED REGORAFENIB DERIVATIVES AS A TYROSINE KINASE INHIBITORS OF LEUKIMIA THROUGH MOLECULAR DOCKING. Frontier in Medical and Health Research, [S. l.], v. 4, n. 3, p. 3863–3874, 2026. Disponível em: https://fmhr.net/index.php/fmhr/article/view/3740.. Acesso em: 21 sep. 2026.